Covid-19: Dr Reddy's engages Indian partners to develop Sputnik V

Sputnik V is also undergoing Phase 3 clinical trials in Russia and other parts of the globe on 40,000 volunteers

Hyderabad-based pharma firm Dr Reddy’s Laboratories (DRL) said it had engaged with partners in India to make the Russian vaccine candidate Sputnik V and is also open to partnering with other global and Indian firms to distribute vaccines or Covid-19 therapies.

Erez Israeli, chief executive officer (CEO) of DRL, said that it had “engaged” with partners in India to manufacture the Sputnik V. 

While Israeli did not divulge details on the partners, he said the data from clinical trials was expected not before March next year. 

“The data from Phase 2 trials here and Phase 3 global trials can be analysed to arrive